Skip to Content
Merck
CN

382172

Histone Deacetylase Inhibitor VI, HNHA

The Histone Deacetylase Inhibitor VI, HNHA, also referenced under CAS 926908-04-5, controls the biological activity of Histone Deacetylase.

Synonym(s):

Histone Deacetylase Inhibitor VI, HNHA, N-Hydroxy-7-(2-naphthylthio)heptanomide

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C17H21NO2S
CAS Number:
Molecular Weight:
303.42
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.54
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Histone Deacetylase Inhibitor VI, HNHA, The Histone Deacetylase Inhibitor VI, HNHA, also referenced under CAS 926908-04-5, controls the biological activity of Histone Deacetylase.

SMILES string

S(CCCCCCC(=O)NO)c1cc2c(cc1)cccc2

InChI

1S/C17H21NO2S/c19-17(18-20)9-3-1-2-6-12-21-16-11-10-14-7-4-5-8-15(14)13-16/h4-5,7-8,10-11,13,20H,1-3,6,9,12H2,(H,18,19)

InChI key

KPNNXHVGOKRBEF-UHFFFAOYSA-N

assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

white

solubility

methanol: 10 mg/mL
DMSO: 100 mg/mL

shipped in

ambient

storage temp.

2-8°C

Quality Level

Disclaimer

Toxicity: Irritant (B)

General description

A cell-permeable hydroxyamide-based SAHA analog that potently inhibits histone deacetylase (HDAC) activity (IC50 = 100 nM). Shown to induce histone acetylation and p21 transcription with concomitent inhibition of cell cycle progression in human fibrosarcoma HT1080 cells. Reported to be more potent than SAHA in inhibiting tumor growth in a murine xenograph model in vivo.

Other Notes

Kim, D.H., et al. 2007. Biochem. Biophys. Res. Commun.356, 233.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Dong Hoon Kim et al.
Biochemical and biophysical research communications, 356(1), 233-238 (2007-03-14)
Histone deacetylase (HDAC), a key enzyme in gene expression and carcinogenesis, is considered an attractive target molecule for cancer therapy. Here, we report a new synthetic small molecule, N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), as a HDAC inhibitor with anti-tumor activity both in

Related Content

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service